The potential global market size and public health value of an HIV-1 vaccine in a complex global market

Vaccine

Volumn 28, Issue 30, 2010, Pages 4786-4797

  Marzetta, Carol A ^a   Lee, Stephen S ^a   Wrobel, Sandra J ^a   Singh, Kanwarjit J ^b   Russell, Nina ^b   Esparza, José ^b  

^a Applied Strategies Consulting   (United States)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Global market size and value; HIV; HIV vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; DRUG COST; DRUG EFFICACY; DRUG MARKETING; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH SERVICE; SCREENING TEST; VACCINE PRODUCTION; VIRUS LOAD; VIRUS TRANSMISSION; ADOLESCENT; ADULT; CHILD; DEVELOPING COUNTRY; ECONOMICS; FEMALE; HEALTH CARE COST; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AIDS VACCINES; CHILD; DEVELOPING COUNTRIES; DRUG COSTS; FEMALE; HEALTH CARE SECTOR; HIV INFECTIONS; HIV-1; HUMANS; MALE; PUBLIC HEALTH; VACCINATION; VIRAL LOAD; YOUNG ADULT;

EID: 77954241872     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.098     Document Type: Article

References (48)

1. Esparza J., Osmanov S. HIV vaccines in a global perspective. Curr Mol Med 2003, 3:183-193.
2. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
3. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
4. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomized, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
5. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
6. Rerks-Ngarm S., Pitisuttithum R., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
7. Dolin R. HIV vaccine trial results-an opening for further research. N Engl J Med 2009, 361:2279-2280.
8. Esparza J. The global HIV vaccine enterprise. Int Microbiol 2005, 8:93-101.
9. WHO, UNICEF, World Bank State of the worlds vaccines and immunization 2009, World Health Organization, Geneva. 3rd ed.
10. World Bank 2007 country income classification [cited 24 October 2007]. Available from http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,contentMDK:204 20458~menuPK:64133156~pagePK:64133150~piPK:64133175~theSitePK:239419,00. html.
11. GAVI Alliance eligible countries [cited 4 December 2009]. Available from http://www.gavialliance.org/support/who/eligible/index.php.
12. Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342:921-929.
13. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-W23.
14. UNAIDS Report on the global AIDS epidemic 2008 2008.
15. UNAIDS 2006 Report on the global AIDS epidemic 2006.
16. Mathers B.M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S.A., et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008, 372(9651):1733-1745.
17. European Monitoring Centre for Drugs and Drug Addiction. Statistical bulletin 2009. Available from: http://www.emcdda.europa.eu/stats09.
18. Caceres C., Konda K., Pecheny M., Chatterjee A., Lyerla R. Estimating the number of men who have sex with men in low and middle income countries. Sex Transm Infect 2006, 82(Suppl. III):iii3-iii9.
19. Smith A.D., Tapsoba P., Peshu N., Sanders E.J., Jaffe H.W. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet 2009, 374:416-422.
20. Van Griensven F., van Wijngaarden J.W.L., Baral S., Grulich A. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 2009, 4:300-307.
21. Soto R.J., Ghee A.E., Nuñez C.A., Mayorga R., Tapia K.A., Astete S.G., et al. Sentinel surveillance of sexually transmitted infections/HIV and risk behaviors in vulnerable populations in 5 Central American countries. J Acquir Immune Defic Syndr 2007, 46(1):101-111.
22. Baral S., Sifakis F., Cleghorn F., Beyrer C. Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review. PLoS Med 2007, 4(12):e339.
23. Centers for Disease Control and Prevention HIV prevalence estimates-United States, 2006. MMWR Morb Mortal Wkly Rep 2008, 57(39):1073-1076.
24. Health Protection Agency Sexually transmitted infections and men who have sex with men in the UK: 2008 report 2008.
25. Cowan S.A., Haff J. HIV and risk behaviour among men who have sex with men in Denmark-the 2006 sex life survey. Euro Surveill 2008, 13(48):pii, 19050.
26. Smith A.M.A., Rissel C.E., Richters J., Grulich A.E., de Visser R.O. Sex in Australia: sexual identity, sexual attraction and sexual experience among a representative sample of adults. Aust NZ J Public Health 2003, 27:138-145.
27. Vandepitte J., Lyerla R., Dallabetta G., Crabbé F., Alary M., Buvé A. Estimates of the number of female sex workers in different regions of the world. Sex Transm Infect 2006, 82:18-25.
28. Walmsley R. International Centre for Prison Studies. World prison population list 2009, 8th ed.
29. International Centre for Prison Studies. Prison brief: female prisoners [cited 29 September 2009]. Available from: http://www.kcl.ac.uk/depsta/law/research/icps/worldbrief/wpb_stats.php?a rea=all&category=wb_female.
30. Dolan K., Kite B., Black E., Aceijas C., Stimson G.V. HIV in prison in low-income and middle-income countries. Lancet Infect Dis 2007, 7:32-41.
31. World Health Organization Effectiveness of interventions to address HIV in prisons 2007.
32. US Census Bureau. Population estimates: population by sex, race, and Hispanic origin; Release date 14 May 2009 [cited 21 October 2009]. Available from: http://www.census.gov/popest/national/asrh/.
33. US Department of Labor, Bureau of Labor Statistics. Labor force statistics from the current population survey. Table 18: Employed persons by detailed industry, sex, race, and Hispanic or Latino ethnicity; 2007 [cited 21 October 2009]. Available from: http://www.bls.gov/cps/cps_aa2007.htm.
34. Centers for Disease Control and Prevention. New estimates of US HIV prevalence, 2006; October 2008 [cited 21 October 2009]. Available from: http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/prevalen ce.htm.
35. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. 2007; 19.
36. Wilburn S.Q., Eijkemans G. Preventing needlestick injuries among healthcare workers. Int J Occup Environ Health 2004, 10:451-456.
37. World Health Organization. Global Health Atlas [cited 28 August 2009]. Available from: http://apps.who.int/globalatlas/dataQuery/default.asp.
38. International Institute for Strategic Studies The military balance 2007 2007, Routledge.
39. Feldbaum H., Lee K., Patel P The national security implications of HIV/AIDS. PLoS Med 2006, 3(6):e171.
40. UNESCO Institute for Statistics. Data Centre [cited 8 September 09]. Available from: http://stats.uis.unesco.org/.
41. CDC Vaccine Price List. Center for Disease Control [cited 4 December 2009]. Available from http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm.
42. Slobod K.S., Coleclough C., Brown S.A., Stambas J., Zhan X., Surman S., et al. Clade, country and region-specific HIV-1 vaccines: are they necessary?. AIDS Res Ther 2005, 2(3). 10.1186/1742-6405r-r2-3.
43. Granados-Gonzalez V., Piedrahita L.D., Martinez-Gutierrez M., Lawrence P., Saoudin H., Zapata X., et al. Neutralizing inter-clade cross-reactivity of HIV-1 V1/V2-specific secretory immunoglobulin A in Colombian and French cohorts. AIDS 2009, 23:2219-2230.
44. Esparza J., Chang M.-L., Widdus R., Madrid Y., Walker N., Ghys P.D. Estimation of " needs" and " probable uptake" for HIV/AIDS prevention vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). Vaccine 2003, 21:2032-2041.
45. Hecht R., Gandhi G. Demand forecasting for preventive AIDS vaccines. Pharmacoeconomics 2008, 26:679-697.
46. UNICEF 2009 vaccine projections: quantities and pricing [cited 4 December 2009]. Available from http://www.unicef.org/supply/files/2009_vaccine_projection.pdf.
47. Stover J., Bollinger L., Hecht R., Williams C., Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Affairs 2007, 26:1147-1158.
48. Forecasting demand for preventive HIV vaccines in India. Policy Research Working Paper #13. International AIDS Vaccine Initiative, 2007.